Surgery pp 697-707 | Cite as

Surgery in the Immunocompromised Patient

  • John Mihran Davis
  • Kathleen King Casey


It is currently estimated that more than 40 million people worldwide are infected with the human immunodeficiency virus (HIV). Although there is no end in sight to the epidemic, current therapeutics have significantly altered the course of the illness. HIV-infected people are much more likely to live longer, less likely to die of opportunistic infections, and more likely to present to the surgical community with relatively well-preserved immune function. Physicians must be not only armed with knowledge on how to protect themselves from inadvertent infection but possess a basic understanding of the disease process and treatment. Patients present with malignancies, end-organ failures, and treatment-related toxicities as well as those illnesses expected in any adult population regardless of immune function. Surgical intervention is routine, and outcome will be influenced by how well we define preoperative risk and understand optimum perioperative management.


Human Immunodeficiency Virus Human Immunodeficiency Virus Infection Human Papilloma Virus Acquire Immune Deficiency Syndrome Human Immunodeficiency Virus Transmission 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ippolito G, Puro V, DeCarli G. The risk of occupational human immunodeficiency virus infection in healthcare workers. Italian Multicenter Study. The Italian Study Group on Occupational Risk of Human Immunodeficiency Virus. Arch Intern Med 1993;153:1451–1458.PubMedCrossRefGoogle Scholar
  2. 2.
    Gerberding J. Management of occupational exposure to blood-borne virus. N Engl J Med 1995;332:444–451.PubMedCrossRefGoogle Scholar
  3. 3.
    Update: acquired immunodeficiency syndrome United States, 1981–1988. MMWR 1989;38:229.Google Scholar
  4. 4.
    Gerberding JL. Clinical practice. Occupational exposure to human immunodeficiency virus in healthcare settings. N Engl J Med 2003;348:826–833.PubMedCrossRefGoogle Scholar
  5. 5.
    Bassett IV, Freedberg SA, Walensky DP. Two drugs or three? Balancing efficacy, toxicity, and resistance in post-exposure prophylaxis or occupational exposure to HIV. Clin Infect Dis 2004;39:395–401.PubMedCrossRefGoogle Scholar
  6. 6.
    Sterilization, disinfection, and antisepsis in the hospital. In: Lenette EH, Balows A, Hausler W, et al, eds. Manual of Clinical Microbiology, 4th ed. Washington, DC: American Society for Microbiology, 1985:129.Google Scholar
  7. 7.
    http// Scholar
  8. 8.
    Jawetz EMJ, Adelberg EA. Antimicrobial chemotherapy. In: Review of Medical Microbiology, 15th ed. Los Altos: Lange Medical, 1982:117.Google Scholar
  9. 9.
    Dodd RY, Notari EP, Stammer SL. Current prevalence and incidence of infectious disease markers and estimated window period risk in the American Red Cross blood donor population. Transfusion 2002;42:975.PubMedCrossRefGoogle Scholar
  10. 10.
    Ho DD, Byington RE, Schooley RT, et al. Frequency of isolation of HTLV-III virus from saliva in AIDS. N Engl J Med 1985;313:1606.PubMedGoogle Scholar
  11. 11.
    Morgan J, Nolan J. Risks of AIDS with artificial insemination. N Engl J Medl 986;314:386.Google Scholar
  12. 12.
    Recommendations for prevention of HIV transmission in healthcare settings. MMWR 1987;36(suppl 2S):1.Google Scholar
  13. 13.
    Guidelines for prevention of transmission of human immunodeficiency virus and hepatitis B virus to health-care and public-safety workers. MMWR 1989;38(suppl S-6):1.Google Scholar
  14. 14.
    Update: acquired immunodeficiency syndrome and human immunodeficiency virus infection among health-care workers. MMWR 1988;37:229.Google Scholar
  15. 15.
    Recommendations for preventing transmission of FHV and HBV to patients during exposure-prone invasive procedures. MMWR 1991;40(suppl RR-8):1.Google Scholar
  16. 16.
    Braathen LR, Ramirez G, Kunze RO, et al. Langerhans cells as primary target cells for HIV infection (letter). Lancet 1987;2:1094.PubMedCrossRefGoogle Scholar
  17. 17.
    McCray E. Occupational risk of the acquired immunodeficiency syndrome among health care workers. N Engl J Med 1986;314:1127.PubMedGoogle Scholar
  18. 18.
    Gerberding JL, Littell C, Tarkington A, et al. Risk of exposure of surgical personnel to patients’ blood during surgery at San Francisco General Hospital. N Engl J Med 1990;322:1788.PubMedGoogle Scholar
  19. 19.
    Quebbeman EJ, Telford GL, Wadsworth K, et al. Double gloving: protecting surgeons from blood contamination in the operating room. Arch Surg 1992;127:213.PubMedGoogle Scholar
  20. 20.
    Tanner J, Parker H. Double-gloving to reduce surgical cross-infection. Cochrane Database Syst Rev 2005;I.Google Scholar
  21. 21.
    Gerbert B, Maguire BT, Hulley SB, Coates TJ. Physicians and acquired immunodeficiency syndrome: what patients think about human immunodeficiency virus in medical practice. JAMA 1989;262:1969.PubMedCrossRefGoogle Scholar
  22. 22.
    Gerberding JL. Clinical practice. Occupational exposure to HIV in health care setting. N Engl J Med 2003;348:826–833.PubMedCrossRefGoogle Scholar
  23. 23.
    Summary: recommendations for preventing transmission of infection with human T-lymphotropic virus type III/lymphadenopathy-associated virus in the workplace. MMWR 1985;34:681.Google Scholar
  24. 24.
    Harpaz R, Seidlein L von, Averhoff FM, et al. Transmission of hepatitis B virus to multiple patients from a surgeon without evidence of inadequate infection control. N Engl J Med 1996;334:549–554.PubMedCrossRefGoogle Scholar
  25. 25.
    The CDC Cooperative Needlestick Surveillance Group. Surveillance of health care workers exposed to blood from patients infected with the human immunodeficiency virus. N Engl J Med 1988;319:1118.Google Scholar
  26. 26.
    Panlilio AL, Shapiro CN, Schable CA, et al. Serosurvey of HIV, HBV, HCV infection among hospital-based surgeons. J Am Coll Surg 1995;180:16.PubMedGoogle Scholar
  27. 27.
    Apparent transmission of human T-lymphotropic virus type III/lymphadenopathy-ssociated virus from a child to a mother providing health care. MMWR 1996;35:76–79.Google Scholar
  28. 28.
    Edlin BR, Irwin KL, Faruque S, et al. Intersecting epidemics: crack cocaine use and HIV infection among inner-city young adults. N Engl J Med 1994;331:1422–1427.PubMedCrossRefGoogle Scholar
  29. 29.
    Public Health Service. Recommendations for Donor Screening with a Licensed Test for HIV-I Antigen. U.S. Department of Health and Human Services. Rockville, MD: Food and Drug Administration, 1995.Google Scholar
  30. 30.
    U.S. Public Health Service guidelines for testing and counseling blood and plasma donors for human immunodeficiency virus type I antigen. MMWR 1996;45(R-22):1.Google Scholar
  31. 31.
    Persistent lack of detectable HIV-I antibody in a person with HIV infections, Utah, 1995. MMWR 1996;45:182.Google Scholar
  32. 32.
    Sexually transmitted diseases. In: Rubenstein FD, ed. Scientific American Medicine, section 7, subsection XXII. New York: Scientific American, 1990.Google Scholar
  33. 33.
    Margulis SJ, Honig CL, Soave R, et al. Biliary tract obstruction in the acquired immunodeficiency syndrome. Ann Intern Med 1986;105:207.PubMedGoogle Scholar
  34. 34.
    Robinson G, Wilson SE, Williams RA. Surgery in patients with acquired immunodeficiency syndrome. Arch Surg 1987;122:170.PubMedGoogle Scholar
  35. 35.
    Barone JE, Gingold BS, Nealon TF, Arvnatis ML. Abdominal pain in patients with acquired immune deficiency syndrome. Ann Surg 1986;204:619–623.PubMedCrossRefGoogle Scholar
  36. 36.
    Davis JM, Mouradian J, Fernandez RJ, et al. Acquired immune deficiency syndromes surgical perspective. Arch Surg 1984;119:90.PubMedGoogle Scholar
  37. 37.
    Rubin R. Acquired immunodeficiency syndrome. In: Rubenstein FD, ed. Scientific American Medicine, section 7, subsection XXH. New York: Scientific American, 1990.Google Scholar
  38. 38.
    Rous P. Transmission of a malignant growth by means of cell-free filtrate. JAMA 1911;56:198.Google Scholar
  39. 39.
    Robert-Guroff M, Nakao Y, Notake K, et al. Natural antibodies to human retrovirus HTLV in a cluster of Japanese patients with adult T-cell leukemia. Science 1982;215:975.PubMedCrossRefGoogle Scholar
  40. 40.
    Martin F, Grulich E, Johanseman AC. Cancer in the population-based cohort of men and women registered homosexual partners. Am J Epidemiol 2003;157:966–972.CrossRefGoogle Scholar
  41. 41.
    Chiao E, Krown S. Update on non-acquired immunodeficiency syndrome defining malignancies. Curr Opin Oncol 2003;15:389–397.PubMedCrossRefGoogle Scholar
  42. 42.
    Berretta M, Cinelli R, Martoletto F, Sbina M, Baccatr E, Tirelli U. Therapeutic approaches to AIDS-related malignancy. Oncogene 2003;22:6646–6659.PubMedCrossRefGoogle Scholar
  43. 43.
    Tsoukas CM, Bernard NF, Abrahamowicz M. Effect of splenectomy on slowing human immunodeficiency virus disease progression. Arch Surg 1998;133:25–31.PubMedCrossRefGoogle Scholar
  44. 44.
    Dega H, Eliaszewicz M, Gisselbrecht M, et al. Infections associated with totally implantable venous access devices (TTVAD) in human immunodeficiency virus-infected patients. J AIDS Hum Retrovirol 1996;13:146–154.Google Scholar
  45. 45.
    Frisch M, Biggar R, Engles E, Goedert J. Association of cancer with AIDS-related immunosupression in adults, JAMA 2002;285:1736–1745.CrossRefGoogle Scholar
  46. 46.
    Grulich AE, Li Y, McDonald A, Correll PKL, Law M, Kalgor JM. Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS 2002;16:1155–1161.PubMedCrossRefGoogle Scholar
  47. 47.
    Hoffman C, Wolf E, Fatkenheuer G, et al. Response to highly active retroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS 2003;17:1521–1529.CrossRefGoogle Scholar
  48. 48.
    Mbulaiteye S, Biggar R, Goedert J, Engel E. Immune deficiency and risk of malignancy among persons with AIDS. J AIDS 2003;32:527–533.Google Scholar
  49. 49.
    Herida M, Mary-Kraus M, Kaphan R, et al. Incidence of non-AIDS defining cancers before and during the highly active retroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003;21:3447–3453.PubMedCrossRefGoogle Scholar
  50. 50.
    Sriplung H, Parkin D. Trends in the incidence of immunodeficiency syndrome-related malignancies in Thailand. Cancer (Phila) 2004;101:2660–2666.PubMedCrossRefGoogle Scholar
  51. 51.
    Shahul E, Abdullah A, McKenna M, Hamers F. AIDS-defining cancers in Western Europe, 1994–2001. AIDS Patient Care 2004;18:501–508.Google Scholar
  52. 52.
    Bonnet F, Lewden C, May T, et al. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active retroviral therapy. Cancer (Phila) 2004;101:317–324.PubMedCrossRefGoogle Scholar
  53. 53.
    Morton F, Biggar R, Engels E, Goedert J. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001;35:1736–1745.Google Scholar
  54. 54.
    Nugent P, O’Connell TX. The surgeon’s role in treating acquired immunodeficiency syndrome. Arch Surg 1986;121:1117–1120.PubMedGoogle Scholar
  55. 55.
    Kaplan JE, Spira TJ, Fishbein DB, Pinsky PF, Schonberger LB. Lymphadenopathy syndrome in homosexual men: evidence for continuing risk of developing the acquired immunodeficiency syndrome. JAMA 1987;257:335.PubMedCrossRefGoogle Scholar
  56. 56.
    Goedert JJ, Biggar RJ, Melbye M, et al. Effect of T4 count and cofactors on the incidence of AIDS in homosexual men infected with human immunodeficiency virus. JAMA 1987;257:331.PubMedCrossRefGoogle Scholar
  57. 57.
    Redfield RR, Burke DS. HIV infection: the clinical picture. Sci Am 1988;259:70–78.Google Scholar
  58. 58.
    Redfield RR, Wright DC, Tramont EC. The Walter Reed staging classification for HTLV-IIII/LAV infection. N Engl J Med 1986;314:131–132.PubMedCrossRefGoogle Scholar
  59. 59.
    Fernandez R, Mouradian J. Metroka C, et al. The prognostic value of histopathology in persistent generalized lymphadenopathy in homosexual men. N Engl J Med 1983;309:185.PubMedGoogle Scholar
  60. 60.
    French AL, Beaudet LM, Benator DA, et al. Cholecystectomy in patients with AIDS: clinicopathologic correlations in 107 cases. Clin Infect Dis 1995;21:852–858.PubMedGoogle Scholar
  61. 61.
    Kavin H, Jonas RB, Chowdhury L, et al. Acalculous cholecystitis and cytomegalovirus infection in the acquired immunodeficiency syndrome. Ann Intern Med 1986;104:53–54.PubMedGoogle Scholar
  62. 62.
    Wilson SE, Robinson G, Williams RA, et al. Acquired immune deficiency syndrome (AIDS): indications for abdominal surgery, pathology, and outcome. Ann Surg 1989;210:428.PubMedCrossRefGoogle Scholar
  63. 63.
    Benator DA, French AL, Beaudet LM, et al. Isospora belli infection associated with acalculous cholecystitis in a patient with AIDS. Ann Intern Med 1994;121:663–664.PubMedGoogle Scholar
  64. 64.
    Lorenz HP, Wilson W, Leigh B, et al. Squamous cell carcinoma of the anus and HIV infection. Dis Colon Rectum 1991;34:336–338.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • John Mihran Davis
    • 1
  • Kathleen King Casey
    • 2
  1. 1.Department of SurgeryJersey Shore University Medical CenterNeptuneUSA
  2. 2.Infectious Disease, Department of MedicineJersey Shore University Medical CenterNeptuneUSA

Personalised recommendations